Download 2019 conference program in pdf

Download 2019 book of abstracts in pdf

Download 2019 invitation in jpg


See the above enclosed pdf for conference time schedule.

Participants:
About 70 researchers and postdocs from European countries, oversees colleagues from the CHDI Foundation and cooperating laboratories, companies supporting biomedical research

Sunday, September 15, 2019

Arrival
Shuttle from Prague Airport to Chateau Liblice will be provided.

Registration, Welcome Drink

Monday, September 16, 2019

Opening of the Conference


Keynote Lecture:


Sandrine Humbert, The Grenoble Institute of Neuroscience, France

Huntington Disease: from brain development to degeneration


Session 1
Neurological Disease, Perspectives from Mammalian cells and Mouse models


Chair: Marta Olejniczak, Co-chair: Marian Hruska-Plochan


Arne Klungland, University of Oslo, Norway

Epitranscriptomic regulation of neurodevelopment


Marian Hruska-Plochan, Zurich, Switzerland

Effect of an anti-GA immunotherapy on poly-GA-expressing human neurons


Magdalena Czeredys, Warsaw, Poland

Disturbances in calcium signaling in the mouse model of Huntington's disease


Marta Olejniczak, Poznan, Poland

Universal RNAi triggers for specific inhibition of mutant huntingtin, ataxin-3, ataxin-7 and atrophin-1 expression

Session 2
Emerging Technologies and Development of Large Animal Models of Diseases


Chair: Bernhard Langwehrmeyer


David Howland, CHDI Foundation, USA

Large Animals in HD: What we have learned; Where we need go next (A CHDI Perspective)


Martin Marsala, San Diego, USA

Spinally-targeted gene therapies for modulation of SOD1 gene mutation-linked ALS and neuropathic pain


Petr Vodicka, Center PIGMOD, IAPG, Czech Republic

Strategies for quantification of mHTT in tissue and biofluid samples of animal models of HD


Helena Kupcova-Skalnikova, Center PIGMOD, Czech Republic

Extracellular vesicles as possible carriers of Huntington´s disease biomarkers? Proteomic study using minipig model

Session 3
Comparative Studies of Huntington’s Disease, Gene and cell therapy of Huntington’s disease


Chair: Edith Phister


G. Bernhard Landwehrmeyer, Ulm, Germany

“We believe that the cure for HD is on the horizon” wrote Nancy Wexler in Hereditary Diseases Foundation 2018 Report. “How Far is the Horizon?”


Edith Pfister, Worcester, MA, USA

Safety and Efficacy of an artificial miRNA targeting Huntingtin in Cynomolgus macaques


Anne Rosser, Cardiff, Great Britain

“Cell repair studies for HD – current status and challenges”


Lodewijk Toonen, uniQure, Holland

A novel AAV-based miQURE gene therapy for SCA3


Stanislav Kukla, Senior Field Marketing Manager, Merck ČR

Discovery depends on detection: current trends in protein biomarker assays

Session 4
Poster Viewing and Presentation


Time-dependent proteomic analysis of cerebrospinal fluid samples from Libechov minipig model of Huntington disease

Poliakh Ievgeniia, Tylečková Jiřina, Červenka Jakub, Novák Jaromír, Valeková Ivona, Vodička Petr


Proteomic analysis of pig brain tissue: evaluation of sample preparation protocols for targeted assay development

Tylečková Jiřina, Kotrčová E., Červenka Jakub, Poliakh Ievgeniia, Novák Jaromír, Vodička Petr


Neural differenciation of human HD and control iPS cells

Kateřina Vodičková Kepková, Petr Vodička


A comparison of conventional culturing membranes with nanofibrous membranes for retinal tissue engineering

Hana Studenovská, Jitka Nováčková, Olga Janoušková, David Rais, Vladimír Proks


Role of CacyBP/SIP in β-catenin homeostasis and HTT aggregation in Huntington’s disease models

Magdalena Czeredys, Ewelina Latoszek, Małgorzata Wiweger, Jan Ludwiczak, Stanisław Dunin-Horkawicz, and Jacek Kuźnicki


Tuesday, September 17, 2019

Session 5
Biomarkers and Molecular Phenotyping in Large Animal Models of Neurodegenerative Diseases


Chair: Melvin Evers


Astrid Valles, uniQure, Holland

Translational efficacy measures of huntingtin lowering in small and large animal models of Huntington’s disease


Zdenka Ellederova, Center PIGMOD, IAPG, Czech Republic

Minipig models of Huntington’s disease at PIGMOD Center – invasive phenotyping


Jiri Klima, Center PIGMOD, Czech Republic

Non-invasive (phenotype) evaluation of TgHD minipigs



Session 6
What Comes the first, DNA Damage or Damaged Mitochondria?


Chair: Arne Klungland


Hana Hansikova, Mitolab, Czech Republic

Mitochondrial phenotype in skeletal muscle of a transgenic minipig model in the early stages of Huntington’s disease


Lars Eide, University of Oslo, Norway

Initial mitochondrial suppression and progressive DNA damage in HD


Michaela Vaskovicova, Center PIGMOD, IAPG, Czech Republic

Double-stranded DNA breaks response in primary fibroblasts from TgHD minipig model of Huntington's disease

Session 7
Retina Distrophy


Chair: Goran Petrovski


Slaven Erceg, Valencia, Spain

Advances in cell therapy for hereditary RPE-related retinal dystrophies


Taras Ardan, Center PIGMPD, IAPG, Czech Republic

RPE replacement - a perspective therapy of retinal neurodegenerative diseases such as age-related macular degeneration (AMD)


Goran Petrovski, University of Oslo, Norway

Retinal pigment epithelium - from basic research to clinical applications


Nik Klymiuk, University of Munich, Germany

A large animal model for USHER syndrome

Closing of the Conference


Wednesday, September 18, 2019

Morning excursion through the PIGMOD Center minipig facility, Pavilion of Surgery unit and Pavilion of Biomedicine will be provided.